Here’s your two-week briefing. IVF is moving beyond chromosomal checks to polygenic and whole-genome embryo screening, while embryo editing draws new funding. A Nature study reports “cognitive Lego” modules in the prefrontal cortex that enable rapid task switching. Greece begins AI-enabled triage on the 1566 national line. AI firms step up neuroscientist hiring for efficiency and interpretability. Humanoid robots progress from pilots to production settings. Teva launches Rise to pilot AI and Industry 4.0 solutions. A meta-analysis finds chatbots often sound more empathic than clinicians.

Taysha Gene Therapies Grants Stock Options to New Employees as Part of Inducement Plan  Quiver Quantitative

SANTA CLARA, Calif.–(BUSINESS WIRE)–ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today announced that shareholders have overwhelmingly approved a 5-for-1 split of the company’s common stock. Shareholders of record as of December 16, 2025, will receive four additional shares for each share held, to be distributed after market close on or about December …

First it was banned. Then its sales blew up. But Horses fails to meet the lofty goals of its own ideas.

Gene therapy Beqvez can help reduce joint bleeds in hemophilia B  Hemophilia News Today

The documentary AlphaGo captures one of the most pivotal moments in the history of artificial intelligence, when AI beat a human at the ancient Chinese game of Go.

Bristol Myers Squibb’s CAR-T therapy Breyanzi has become the first such treatment approved for patients with a rare, slow-growing type of non-Hodgkin lymphoma. The drug was approved Thursday for third-line patients with marginal zone lymphoma ...

Gene Therapy for Duchenne: Translating clinical guidance into meaningful patient understanding  Muscular Dystrophy Association

Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Blue Owl Capital Inc. (“Blue Owl” or “the Company”) (NYSE: OWL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of …

The FDA’s reported plan to move toward single-trial approvals has stirred industry concern, but one analyst views the proposal as a catalyst for greater R&D investment in the sector.

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome  Bakersfield.com

The past year has marked a turning point in the corporate AI conversation. After a period of eager experimentation, organizations are now confronting a more complex reality: While investment in AI has never been higher, the path from pilot to production remains elusive. Three-quarters of enterprises remain stuck in experimentation mode, despite mounting pressure to…

AI adoption is an irreversible trend in corporate America, driven by the promise of increased productivity. We decided to try it. Our specific focus was Agentic AI, autonomous systems capable of planning, reasoning and executing a sequence of actions, which we attempted to implement at our organization.   The goal at Kids Included Together, a nonprofit …

A panel of CDC vaccine advisors has stopped recommending that all children receive the hepatitis B vaccine at birth, overruling scientific consensus and public health officials who pleaded that there was no grounded rationale for ...

AI startups say the promise of turning dazzling models into useful products is harder than anyone expected. Three founders discuss what it takes.

Get ready for SABCS25 with LucidQuest’s concise preview of the sessions and themes shaping breast cancer research this year. We […] The post SABCS 2025 Preview: Key Breast Cancer Highlights to Watch appeared first on LucidQuest Ventures.

Cell & Gene Therapy CRO Market to Reach USD 9.82 Billion by 2034 Amid Rising Outsourcing of Advanced Therapies  openPR.com

NEW YORK–(BUSINESS WIRE)–MM+M has announced its seventh class of 40 Under 40 honorees. The program shines a light on the young marketers whose leadership, strategic thinking and digital facility have contributed to the industry’s continued growth at a challenging time for the healthcare business as a whole. The 40 Under 40 list includes individuals who …

As we approach 2026, it’s a great moment to reflect on the past year. For those with a Garmin watch, The post The no cost route to viewing your Garmin annual summary appeared first on Gadgets & Wearables.

This fortnight, new data highlights a nasal spray pertussis vaccine showing strong mucosal and systemic immunity, while ILiAD’s BPZE1 candidate demonstrates significant protection in a human challenge model. Emerging evidence suggests the shingles vaccine may slow dementia progression, offering potential therapeutic benefits beyond infection prevention. Additional updates include WHO’s endorsement of GC Biopharma’s MAV/06 varicella strain and India’s regulatory review of a proposed cancer vaccine trial—signaling meaningful advances across prevention, innovation, and global immunization strategies.

A new biotech has raised $100 million to build a mix of assets from inside and outside China, while developing its own drug candidates. The Shanghai-based startup, called OTR Therapeutics, is a new twist on ...

Novartis exec: Itvisma approval ‘important moment’ for community  SMA News Today

The trading technology market is experiencing a significant shift. What worked five years ago – basic charting with a handful of analysis tools – no longer satisfies traders who’ve grown accustomed to automation, advanced analytics, and seamless data integration. This platform established itself as the industry standard for good reason: excellent charts, a massive community, …

Background: Deep learning models have the potential to enable fast and consistent interpretations of scoliosis radiographs. This study aims to assess the impact of deep learning assistance on the speed and accuracy of clinicians in measuring major coronal curves on scoliosis radiographs. Methods: We utilized a deep learning model (Context Axial Reverse Attention Network, or CaraNet) to assist in measuring Cobb’s angles on scoliosis radiographs in a simulated clinical setting. Four trainee radiologists with no prior experience and four trainee orthopedists with four to six months of prior experience analyzed the radiographs retrospectively, both with and without deep learning assistance, using a six-week washout period. We recorded the interpretation time and mean angle differences, with a consultant spine surgeon providing the reference standard. The dataset consisted of 640 radiographs from 640 scoliosis patients, aged 10–18 years; we divided the dataset into 75% for training, 16% for validation, and 9% for testing. Results: Deep learning assistance achieved non-statistically significant improvements in mean accuracy of 0.32 for trainee orthopedists (95% CI −1.4 to 0.8, p > 0.05) and 0.43 degrees (95% CI −1.6 to 0.8, p > 0.05) for trainee radiologists (non-inferior across all readers). Mean interpretation time decreased by 13.25 s for trainee radiologists, but increased by 3.85 s for trainee orthopedists (p = 0.005). Conclusions: Deep learning assistance for measuring Cobb’s angles was as accurate as unaided interpretation and slightly improved measurement accuracy. It increased the interpretation speeds of trainee radiologists but slightly slowed trainee orthopedists, suggesting that its effect on speed depended on prior experience.